Mr. Simon Castonguay reports

LUMIERA REPORTS FIRST HALF OF 2022 RESULTS WITH A 40% INCREASE COMPARED TO PREVIOUS YEAR

Lumiera Health Inc. 's corporate strategy and plans, which were put place in 2021, are continuing to prove successful, with Lumiera's first half of 2022 improving its sales by over 40 per cent compared with last-year first-half results.

The increase in the company's sales has been driven by increased retail and on-line distribution, which has led to trial and repeat purchases of Awaye natural pain relief cream and Bazzzics, a natural non-addictive sleep aid.

"We are very proud to see that the strategies and plans we put together and have been executing are driving considerable growth, both in on-line and retail channels," says Carlos Ponce, chief executive officer of Lumiera Health. "It's also exciting to see that the two product we launched last year, Awaye pain relief cream and Bazzzics natural sleep aids, have quickly become important revenue drivers. As we keep expanding national distribution and begin sales in the U.S., we look forward to continuing our growth."

Q2 financial statements will be released on or before July 29, 2022.

Increased working capital through new debt agreement

As a part of its accelerate growth plan, Lumiera is continuing to identify savings and allocate those saving to inventory to support growth. With that focus, the company entered into an agreement with shareholders and members of management, for a total amount of $293,000. This amount will be used to free up cash flow in the short term; the new loan has a one-year term and pays monthly interest at 15 per cent.

The lenders will receive a total of five million non-transferable warrants. Each warrant will entitle the holder to acquire one common share, at an exercise price of five cents per share, for a period of one year ending July 5, 2023. The warrants will, unless exercised, expire on the 30th day after the company pays back the note.

The new loan is subject to certain standard conditions, including, but not limited to, the receipt of all necessary approvals, including the acceptance of the TSX Venture Exchange.

About Lumiera Health Inc.

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The company is also commercializing a unique topical product line acting on the endocannabinoid system, without the use of cannabis, that provides an innovative solution for chronic pain and inflammation. A pioneer in the natural health innovation space, the Lumiera brand is rooted in the core values of science, nature and compassion. The company's goal is to make people's lives better by developing natural health and wellness products that are effective, safe and trustworthy.

We seek Safe Harbor.